Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CAD/USD

    0.7308
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • Bitcoin CAD

    86,077.82
    +5,007.55 (+6.18%)
     
  • CMC Crypto 200

    1,359.23
    +82.25 (+6.44%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Endo International’s Specialty and Established Products in Q1

Endo International’s Specialty and Established Products in Q1

Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.